Drug safety in Africa: a review of systems and resources for pharmacovigilance

IntroductionPharmacovigilance on the African continent has developed over time, with 50 of the 54 countries currently being members of the WHO Programme for international drug monitoring. However, there are still challenges, such as weak regulation, insufficient resources, and differing policies. This expert opinion provides unique insights from long-term experience overcoming some of these challenges and proposes some solutions for implementing pharmacovigilance in resource-limited settings.Areas coveredThis was an expert opinion on the pharmacovigilance landscape in Africa with a focus on reporting, good pharmacovigilance practice inspections, resources available, and the adoption of artificial intelligence. The literature search for the review was carried out in June 2023 on selected electronic databases that included PubMed, Embase, and Web of Science to identify relevant literature published from 2017 up to date while the expert opinion is an informed position from decades of practice in the area.Expert Opinion/CommentaryAfrican countries are at different maturity levels and pharmacovigilance competence. A few countries have outstanding pharmacovigilance systems, while the majority do not have fully functional systems. African countries may pool resources through regional blocs to implement joint pharmacovigilance activities. With advancements in technology, countries are expected to embrace artificial intelligence to ensure sustainable pharmacovigilance practices.

Automated summary

Pharmacovigilance in Africa has grown over time, with the majority of countries being members of the WHO Programme for international drug monitoring. However, challenges such as weak regulation, insufficient resources, and differing policies still exist. This expert opinion offers insights from long-term experience and suggests solutions for implementing pharmacovigilance in resource-limited settings.